or Login to see your representatives.

Access Candidates' and Representatives' Biographies, Voting Records, Interest Group Ratings, Issue Positions, Public Statements, and Campaign Finances

Simply enter your zip code above to get to all of your candidates and representatives, or enter a name. Then, just click on the person you are interested in, and you can navigate to the categories of information we track for them.

Public Statements

John Dingell's Public Statements on Issue: Drugs

Full Name: John D. Dingell
Office: U.S. House (MI) - District 12, Democratic
First Elected: 12/13/1955
Last Elected: 11/06/2012
Next Election: 2014
Gender: Male
Family: Wife: Debbie; 4 Children: John, Chris, Jennifer, Jeanne
Birth Date: 07/08/1926
Birth Place: Colorado Springs, CO
Home City: Dearborn, MI
Religion: Catholic
Date Title
Issue Position: Health Care
Issue Position: Prescription Drugs
May 7, 2013 Dingell Statement on Prescription Drug "Track & Trace" Markup
June 20, 2012 Food and Drug Administration Safety and Innovation Act
June 12, 2012 Dingell, UM Professor Dr. Johnston To Discuss $7M Grants from HHS
May 30, 2012 User Fee Bill Co-Authored by Dingell Passes House
Dec. 8, 2011 Dingell Applauds Generic Drug User Fee Act (GDUFA) Commitment to Drug Safety and Accessibility
Sept. 23, 2011 Dingell: Drug Shortages Leading to Quality Issues in Nation's Drugs
July 7, 2011 Dingell: FDA Confirms Authorities and Funding Included in H.R. 1483 Will Help to Prevent Another Heparin-Like Event
June 16, 2011 Letter to The Honorable John Boehner, Speaker of the US House of Representatives
June 16, 2011 House Democratic Leaders Introduce Legislation to Save More Than $100 Billion in Medicare Drug Costs
June 16, 2011 House Democratic Leaders Introduce Legislation to Save More than $100 Billion in Medicare Drug Costs
June 15, 2011 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012
April 12, 2011 Dingell, Waxman, Pallone, & DeGette Introduce Drug Safety Enhancement Act
Dec. 21, 2010 FDA Food Safety Modernization Act
Dec. 17, 2010 Dingell, Waxman, Pallone, & Stupak Introduce Drug Safety Legislation
Dec. 8, 2010 Full-year Continuing Appropriations Act, 2011
Sept. 20, 2010 Waxman, Dingell, Pallone & Stupak Open Discussion on Potentially Historic Changes in Drug Safety Laws
Aug. 27, 2010 Statement on GAO'S Clinical Trials Report
May 27, 2010 Dingell Stresses Need For Additional Drug Safety Authorities
July 30, 2009 Providing for Consideration of H.R. 2749, Food Safety Enhancement Act of 2009
June 23, 2009 Panel II Of A Hearing Of The Health Subcommittee Of The House Energy And Commerce Committee - Comprehensive Health Reform
June 12, 2009 Dingell Praises ‘Family Smoking Prevention And Tobacco Control Act.'
June 11, 2009 Hearing Of The Health Subcommittee Of The House Energy And Commerce Committee - Emerging Health Care Issues: Follow-On Biologic Drug Competition
May 1, 2009 Hearing Of The Health Subcommittee Of The House Energy And Commerce Committee - The 2009 H1N1 Flu Outbreak And The United States Federal Response
July 17, 2008 Dingell, Stupak Question Whether FDA Knowingly Allowed Potentially Unsafe & Ineffective Drugs into the U.S. Marketplace
May 1, 2008 Panel I of a Hearing of the Health Subcommittee of the House Energy and Commerce Committee - Drug Safety Provisions of the Food and Drug Administration Globalization Act Discussion Draft Legislation
April 30, 2008 Hearing of the Oversight and Investigations Subcommittee of the House Energy and Commerce Committee - The Heparin Disaster: Chinese Counterfeits and American Failures
April 22, 2008 Panel I of a Hearing of the Oversight and Investigations Subcommittee of the House Energy and Commerce Committee - The Food and Drug Administration's Foreign Drug Inspection Program
April 22, 2008 Subcommittee on Oversight and Investigations Hearing Entitled "FDA's Foreign Drug Inspection Program: Weaknesses Place Americans at Ri"sk
Feb. 21, 2008 Dingell, Stupak Consider Changing Law Over Heparin Failures
Feb. 7, 2008 Committee Continues Investigation into Celebrity Drug Endorsements
Jan. 25, 2008 Dingell, Stupak Comment on FDA Plan for Overseas Inspections
Jan. 23, 2008 Dingell, Stupak Comment on Decision to Pull Vytorin Ads
Jan. 7, 2008 Committee Opens Investigation into Celebrity Drug Endorsements
Nov. 1, 2007 Hearing of the Subcommittee on Oversight & Investigations of the House Committee on Energy and Commerce - FDA Foreign Drug Inspection Program
Sept. 26, 2007 Hearing of the Subcommittee on Health of the House Committee on Energy and Commerce - H.R. 3610, The Food and Drug Import Safety Act
Sept. 20, 2007 Dingell Introduces H.R. 3610, the "Food and Drug Import Safety Act of 2007"
Sept. 19, 2007 Food and Drug Administration Amendments Act of 2007
Aug. 2, 2007 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008
July 31, 2007 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008-- Continued
July 25, 2007 Dingell, Stupak Respond to Attempted Retaliation Against Congressional Witnesses by Food and Drug Administration Official
July 17, 2007 Opening Statement: House Committee On Energy And Commerce, Subcommittee On Oversight And Investigations: Can The FDA Assure The Safety And Security ..
July 11, 2007 Food And Drug Administration Amendments Act Of 2007
June 21, 2007 Statement of Congressman John D. Dingell, Chairman Committee on Energy and Commerce - Committee on Energy and Commerce Markup on PDUFA, MDUFA, and Ot
June 11, 2007 Letter to The Honorable Andrew C. von Eschenbach, M.D., Commissioner, Food and Drug Administration, Department of Health and Human Services
May 21, 2007 Dingell, Stupak Question FDA & Glaxo for Failing to Warn Diabetics of Dangers of Avandia
May 9, 2007 Subcommitee on Health Hearing Entitled "Assessing the Safety of Our Nation's Drug Supply"
May 2, 2007 Subcommittee on Commerce, Trade, and Consumer Protection Hearing Entitled "HR 1902, Protecting Consumer Access to Generic Drugs Act of 2007"
March 22, 2007 Statement of the Honorable John D. Dingell: Subcommittee on Oversight and Investigations Hearing on "The Adequecy of the FDA Efforts to Assure the..."
Back to top